Please use this identifier to cite or link to this item:
https://doi.org/10.1111/1756-185X.13446
DC Field | Value | |
---|---|---|
dc.title | COST-EFFECTIVENESS OF AN ADHERENCE-ENHANCING INTERVENTION FOR GOUT BASED ON REAL-WORLD DATA | |
dc.contributor.author | Lin, LW | |
dc.contributor.author | Teng, GG | |
dc.contributor.author | Lim, AYN | |
dc.contributor.author | Yoong, JSY | |
dc.contributor.author | Zethraeus, N | |
dc.contributor.author | Wee, HL | |
dc.date.accessioned | 2019-06-07T02:12:37Z | |
dc.date.available | 2019-06-07T02:12:37Z | |
dc.date.issued | 2019-04-01 | |
dc.identifier.citation | Lin, LW, Teng, GG, Lim, AYN, Yoong, JSY, Zethraeus, N, Wee, HL (2019-04-01). COST-EFFECTIVENESS OF AN ADHERENCE-ENHANCING INTERVENTION FOR GOUT BASED ON REAL-WORLD DATA 22 (4) : 545-554. ScholarBank@NUS Repository. https://doi.org/10.1111/1756-185X.13446 | |
dc.identifier.issn | 1756-1841 | |
dc.identifier.issn | 1756-185X | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/155410 | |
dc.description.abstract | © 2018 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. Aim: Medication non-adherence influences outcomes of therapies for chronic diseases. Allopurinol is a cornerstone therapy for patients with gout; however, non-adherence to allopurinol is prevalent in Singapore and limits its effectiveness. Between 2008-2010, an adherence-enhancing program was implemented at the rheumatology division of a public tertiary hospital. The cost-effectiveness of this program has not been fully evaluated. With healthcare resources being finite, the value of investing in adherence-enhancing interventions should be ascertained. This study aims to evaluate the cost-effectiveness of this adherence-enhancing program to inform optimal resource allocation toward better gout management. Method: Adopting a real-world data approach, we utilized patient clinical and financial records generated in their course of routine care. Intervention and control groups were identified in a standing database and matched on nine risk factors through propensity score matching. Cost and effect data were followed through 1-2 years. A decision tree was developed in TreeAge using a societal perspective. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty. Results: At an assumed willingness-to-pay threshold of $50 000 USD ($70 000 SGD) per quality-adjusted life year (QALY), the intervention had an 85% probability of being cost-effective compared to routine care. The incremental cost-effectiveness ratio was $12 866 USD per QALY for the base case and ranged from $4 139 to $21 593 USD per QALY in sensitivity analyses. Conclusion: The intervention is cost-effective in the short-term, although its long-term cost-effectiveness remains to be evaluated. | |
dc.publisher | Wiley | |
dc.source | Elements | |
dc.subject | allopurinol | |
dc.subject | cost-effectiveness analysis | |
dc.subject | electronic medical records | |
dc.subject | gout | |
dc.subject | medication adherence | |
dc.subject | quality-adjusted life year | |
dc.type | Article | |
dc.date.updated | 2019-06-04T07:23:55Z | |
dc.contributor.department | SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH | |
dc.contributor.department | MEDICINE | |
dc.contributor.department | PHARMACY | |
dc.description.doi | 10.1111/1756-185X.13446 | |
dc.description.volume | 22 | |
dc.description.issue | 4 | |
dc.description.page | 545-554 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Lin_et_al-2019-International_Journal_of_Rheumatic_Diseases.pdf | Published version | 891.79 kB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.